Cargando…
Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy
Patients with malignant tumors frequently suffer during disease progression from a syndrome referred to as cancer cachexia (CaCax): CaCax includes skeletal muscle atrophy and weakness, loss of bodyweight, and fat tissues. Currently, there are no FDA (Food and Drug Administration) approved treatments...
Autores principales: | Adams, Volker, Gußen, Victoria, Zozulya, Sergey, Cruz, André, Moriscot, Anselmo, Linke, Axel, Labeit, Siegfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600862/ https://www.ncbi.nlm.nih.gov/pubmed/33050629 http://dx.doi.org/10.3390/cells9102272 |
Ejemplares similares
-
Regulation of Glucose Metabolism by MuRF1 and Treatment of Myopathy in Diabetic Mice with Small Molecules Targeting MuRF1
por: Labeit, Siegfried, et al.
Publicado: (2021) -
Expression of MuRF1 or MuRF2 is essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model
por: Nguyen, Thanh, et al.
Publicado: (2020) -
Small‐molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia
por: Bowen, Thomas Scott, et al.
Publicado: (2017) -
Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2
por: Witt, Christian C, et al.
Publicado: (2008) -
Small‐molecule‐mediated chemical knock‐down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure
por: Adams, Volker, et al.
Publicado: (2019)